EMA
approval
· 2026-01-21
EMA Authorised: Lacosamide Adroiq (lacosamide) — Extrovis EU Ltd
Summary
The European Medicines Agency authorised Lacosamide Adroiq for the treatment of epilepsy, with Extrovis EU Ltd as the marketing authorization holder.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Epilepsy. MAH: Extrovis EU Ltd. Decision date: 21/01/2026